Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19: A Phase II Clinical Trial
Latest Information Update: 16 Feb 2024
At a glance
- Drugs DB-001 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms EMOTE
- Sponsors Direct Biologics
- 23 Dec 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 23 Aug 2022 Planned End Date changed from 7 Dec 2022 to 7 Mar 2023.
- 23 Aug 2022 Planned primary completion date changed from 7 Dec 2022 to 7 Mar 2023.